Geode Capital Management LLC purchased a new position in Upstream Bio, Inc. (NASDAQ:UPB - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 363,269 shares of the company's stock, valued at approximately $5,973,000. Geode Capital Management LLC owned 0.68% of Upstream Bio as of its most recent SEC filing.
Several other large investors also recently bought and sold shares of the company. Moody Aldrich Partners LLC bought a new stake in shares of Upstream Bio in the 4th quarter worth about $1,229,000. Corebridge Financial Inc. bought a new stake in Upstream Bio in the fourth quarter valued at about $142,000. Bank of New York Mellon Corp acquired a new stake in Upstream Bio during the fourth quarter valued at approximately $607,000. Rhumbline Advisers bought a new position in Upstream Bio during the 4th quarter worth approximately $275,000. Finally, JPMorgan Chase & Co. acquired a new position in shares of Upstream Bio in the 4th quarter worth approximately $786,000.
Upstream Bio Stock Performance
Shares of UPB stock traded up $0.20 on Tuesday, hitting $8.98. 216,944 shares of the stock traded hands, compared to its average volume of 324,457. The company's fifty day moving average is $7.88 and its 200 day moving average is $14.41. Upstream Bio, Inc. has a 1-year low of $5.14 and a 1-year high of $29.46.
Upstream Bio Company Profile
(
Free Report)
Upstream Bio, Inc, a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease.
See Also
Before you consider Upstream Bio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Upstream Bio wasn't on the list.
While Upstream Bio currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
